Alpha memo: metformin resistance protocol mismatch

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Clarify that the 'mismatch' is between a morphological endpoint (hypertrophy) and a metabolic endpoint (HbA1c), rather than a conflicting signal on the same physiological process.
2. Explicitly state that Receipt 2 does not provide a clear signal for resistance training alone in metformin users, as the abstract provided focuses on aerobic training results.

Minor issues

• The synthesis attempts to contrast muscle hypertrophy (Receipt 1) with HbA1c reduction (Receipt 2), which are fundamentally different biological endpoints, making the 'mismatch' claim more of a comparison of different outcomes than a contradiction of the same signal.

Reviewer note

The memo identifies an interesting tension between the blunting of muscle hypertrophy (Receipt 1) and the maintenance of glycemic benefits from aerobic exercise (Receipt 2) in metformin users. However, the 'mismatch' is framed as a protocol/modality conflict when it is actually a contrast between two entirely different endpoints (muscle mass vs. HbA1c). Furthermore, the memo claims Receipt 2 indicates signals 'diverge by training modality,' but the provided excerpt only explicitly confirms the aerobic training result for metformin users; the resistance-only result is not detailed, making the 'divergence' claim partially unsupported by the provided text. The author correctly identifies the population and endpoint confounds in the caveats, which is a strength.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis